Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
CONCLUSION: Nine months of treatment with orlistat and sibutramine not only reduced weight but also significantly improved BMI, WC, BF, VF, FPG, adiponectin, fasting insulin, HOMA%B, HOMA%S, HOMA-IR and hs-CRP. These improvements could prove useful in the reduction of metabolic and cardiovascular risks in obese subjects.
PMID: 28724846 [PubMed - in process]
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Al-Tahami BAM, Al-Safi Ismail AA, Sanip Z, Yusoff Z, Shihabudin TMT, Singh TSP, Rasool AHG Tags: J Nippon Med Sch Source Type: research
More News: Alli | Cardiology | Cardiovascular | Eating Disorders & Weight Management | Heart | Insulin | Malaysia Health | Meridia | Obesity | Pancreas | Study | Universities & Medical Training | Xenical